Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcilis PRRS
- Development stage
- Unknown
- Lead developer
- Intervet
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
Porcilis PRRS is a live attenuated freeze-dried vaccine for pigs, indicated for active immunization against European strains of Porcine Reproductive and Respiratory Syndrome (PRRS) virus. It aims to reduce viremia, improve reproductive performance in breeding pigs, and improve rearing results in finishing pigs by reducing morbidity, improving daily growth, and feed conversion. It was originally part of Novartis Animal Health's portfolio, which was acquired by Elanco Animal Health in 2015. However, current information indicates that MSD Animal Health is the developer and manufacturer of the vaccine.
- Brand names
- Porcilis PRRS
Beyond the preview
Go deeper on Porcilis PRRS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Porcilis PRRS.